Skip to main content
. Author manuscript; available in PMC: 2018 Aug 15.
Published in final edited form as: Clin Cancer Res. 2017 May 3;23(16):4556–4568. doi: 10.1158/1078-0432.CCR-16-2821

Figure 2. Tumor associated antigen (TAA) expression profiles in NSCLC patients and HLA restricted synthetic peptides of TAA used for IFN-γ ELISPOT assay.

Figure 2

(A) Lung tumor biopsy for 16 patients was performed on day 0 and day 7 after the vaccine administration and tumor associated antigen expression profiles were determined by qRT-PCR using the tumor antigen panel as described in Material and Methods. Over expression of TAA was defined as an expression of more than 100 gene copies per 106 β-actin gene copies. Percentage of patients that overexpress each TAA were shown. (B) Patients’ HLA matched tumor associated antigen derived synthetic peptides were selected and added to the 96 well plate of INF-γ ELISPOT assay. Six of 16 patients showed immune responses to TAA specific INF-γ production.